sur OXURION (EBR:OXUR)
Oxurion announces its software strategy with Exagis
The Leuven-based biopharmaceutical company Oxurion is launching a software-driven growth strategy, highlighting Exagis, its clinical data management platform. Initially developed to manage internal trial data, Exagis is now expanding to a broader market, integrating more than 16,000 patients and 600 clinical centers.
Recent developments have enabled Exagis to be marketed independently, generating separate software revenue for Oxurion. This platform captures operational experience, enriching its software ecosystem, which will soon be complemented by an eTMF module scheduled for July 2026.
Oxurion also plans to integrate artificial intelligence capabilities to optimize efficiency and compliance in clinical research. The goal is to strengthen its position as a robust and scalable technology platform.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de OXURION